GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (FRA:69C0) » Definitions » E10

Cara Therapeutics (FRA:69C0) E10 : €-17.57 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cara Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was €-2.487. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-17.57 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-01-19), Cara Therapeutics's current stock price is €4.836. Cara Therapeutics's E10 for the quarter that ended in Sep. 2024 was €-17.57. Cara Therapeutics's Shiller PE Ratio of today is .


Cara Therapeutics E10 Historical Data

The historical data trend for Cara Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics E10 Chart

Cara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -19.15 -19.60

Cara Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.19 -19.60 -21.74 -22.78 -17.57

Competitive Comparison of Cara Therapeutics's E10

For the Biotechnology subindustry, Cara Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Shiller PE Ratio falls into.



Cara Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cara Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-2.487/133.0289*133.0289
=-2.487

Current CPI (Sep. 2024) = 133.0289.

Cara Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -1.752 99.070 -2.353
201503 -2.328 99.621 -3.109
201506 -2.673 100.684 -3.532
201509 -2.031 100.392 -2.691
201512 -3.856 99.792 -5.140
201603 -4.203 100.470 -5.565
201606 -5.126 101.688 -6.706
201609 -4.491 101.861 -5.865
201612 -9.215 101.863 -12.034
201703 -9.088 102.862 -11.753
201706 -3.097 103.349 -3.986
201709 -3.826 104.136 -4.888
201712 -4.360 104.011 -5.576
201803 -4.963 105.290 -6.271
201806 -5.341 106.317 -6.683
201809 -5.245 106.507 -6.551
201812 -5.485 105.998 -6.884
201903 -5.947 107.251 -7.376
201906 -6.160 108.070 -7.583
201909 -8.063 108.329 -9.901
201912 -6.588 108.420 -8.083
202003 -6.733 108.902 -8.225
202006 -5.754 108.767 -7.037
202009 -3.566 109.815 -4.320
202012 16.670 109.897 20.179
202103 -4.738 111.754 -5.640
202106 -6.076 114.631 -7.051
202109 -0.204 115.734 -0.234
202112 -6.691 117.630 -7.567
202203 -5.666 121.301 -6.214
202206 -0.908 125.017 -0.966
202209 -5.212 125.227 -5.537
202212 -6.344 125.222 -6.740
202303 -5.492 127.348 -5.737
202306 -6.424 128.729 -6.639
202309 -5.847 129.860 -5.990
202312 -6.492 129.419 -6.673
202403 -6.182 131.776 -6.241
202406 -4.125 132.554 -4.140
202409 -2.487 133.029 -2.487

Add all the adjusted EPS together and divide 10 will get our e10.


Cara Therapeutics  (FRA:69C0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cara Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics Business Description

Traded in Other Exchanges
Address
400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Cara Therapeutics Headlines

No Headlines